HBV-related liver cancer trial using immune cells with or without lenvatinib
Treatments studied
Part of Cancer, Digestive system, Infections clinical trials.
This trial tests lab-made immune T cells that target hepatitis B (HBV) using a treatment called LioCyx-M, either alone or with lenvatinib. It’s for people with advanced HBV-related hepatocellular carcinoma (liver cancer) who can’t be cured with surgery or local procedures.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced liver cancer caused by hepatitis B, confirmed by tissue sample or liver disease clinical standards for cirrhosis
- Your health and daily functioning are fairly good (ECOG score 0 or 1)
- Your liver disease is either not cirrhosis or is compensated (Child-Pugh A, 5–6 points)
- You have hepatitis B surface antigen (HBsAg) in your blood
- You must not have brain metastases, and you must have enough vein access for study treatments and blood/samples
- You must match the trial’s immune-cell “HLA” fit (your blood type for immune recognition must match their available T-cell receptors)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new immune cell therapy (LioCyx-M) for people with advanced liver cancer caused by hepatitis B. It uses specially designed T cells (a type of immune cell) that target the hepatitis B virus and may help fight the cancer.
This Phase 2 study tests lenvatinib plus an immunotherapy drug (tislelizumab) in people with advanced liver cancer that cannot be removed by surgery and who have hepatitis B infection. The goal is to see if this combination can shrink tumors and slow the cancer down, and to study helpful blood/biomarker signals.
This Phase 1 study tests a lab-made immune cell treatment that targets hepatitis B (HBV)–related liver cancer. It may help by directing the body’s immune system to attack the cancer, while carefully checking safety.
This trial tests using your own immune cells (tumor-infiltrating lymphocytes) to fight advanced liver cancer. It may help if you have Barcelona Clinic Liver Cancer (BCLC) stage B or C and your liver function is still fairly good.
This Phase 2 study tests whether combining three treatments—lenvatinib, tislelizumab, and a liver-directed chemotherapy approach (HAIC)—can shrink advanced hepatocellular carcinoma. It may help people whose cancer is stage C and hasn’t been treated before.
This trial tests adding lenvatinib (a targeted therapy pill) to a combination of two immunotherapy drugs (durvalumab and tremelimumab) for people with liver cancer that cannot be removed by surgery. The goal is to see if the three-drug approach works better than the two immunotherapy drugs alone.
Hear when a new Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.